Thursday, September 15, 2016

BRIEF-Acelrx reports positive results for ARX-04 in Phase 3 registration trial

* Reports positive results for ARX-04 (sufentanil sublingual

tablet, 30 mcg), including in elderly patients and patients with

organ impairment, in third Phase 3 registration trial, SAP303

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)